 "Zydus acquires derma brand Melgain from Issar Pharma")
Cadila Healthcare surged 4% to Rs 391 on the BSE after the pharmaceutical company said that its oral solid dosage drug manufacturing plant located at SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA).
“The EIR received following the inspection carried out in January 2016. The receipt of EIR indicates the successful closure of the inspection points (483s) raised,” Cadila Healthcare said in a press release.
It may be mentioned that this plant is a separate manufacturing unit and does not form a part of the Moraiya formulations manufacturing facility, it added.
At 10:29 am, the stock was up 3% at Rs 386 on the BSE. A combined 854,866 shares changed hands on the counter on the BSE and NSE so far.
“The EIR received following the inspection carried out in January 2016. The receipt of EIR indicates the successful closure of the inspection points (483s) raised,” Cadila Healthcare said in a press release.
It may be mentioned that this plant is a separate manufacturing unit and does not form a part of the Moraiya formulations manufacturing facility, it added.
At 10:29 am, the stock was up 3% at Rs 386 on the BSE. A combined 854,866 shares changed hands on the counter on the BSE and NSE so far.
